Literature DB >> 2313671

Minocycline treatment for rheumatoid arthritis: an open dose finding study.

F C Breedveld1, B A Dijkmans, H Mattie.   

Abstract

Ten patients with active definite or classical rheumatoid arthritis (RA) were treated with oral minocycline (maximal daily dose 400 mg) during 16 weeks in an open study. Seven patients reported side effects (in most cases vestibular) leading to premature discontinuation in one. Half of the efficacy variables improved significantly after 4 weeks of therapy. At the end of the study all variables were significantly changed compared with their pretreatment values. We conclude that minocycline may be beneficial in RA. This effect needs to be confirmed in controlled studies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2313671

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Benefits and risks of minocycline in rheumatoid arthritis.

Authors:  P Langevitz; A Livneh; I Bank; M Pras
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential.

Authors:  K Suomalainen; T Sorsa; L M Golub; N Ramamurthy; H M Lee; V J Uitto; H Saari; Y T Konttinen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis.

Authors:  H A Capell; M Brzeski
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

4.  Inhibitory effect of cephalothin on matrix metalloproteinase activity around loose hip prostheses.

Authors:  S Santavirta; M Takagi; Y T Konttinen; T Sorsa; A Suda
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Human gelatinase B, a marker enzyme in rheumatoid arthritis, is inhibited by D-penicillamine: anti-rheumatic activity by protease inhibition.

Authors:  K Norga; B Grillet; S Masure; L Paemen; G Opdenakker
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

6.  Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood.

Authors:  S Milano; F Arcoleo; P D'Agostino; E Cillari
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis.

Authors:  A Lauhio; Y T Konttinen; H Tschesche; D Nordström; T Salo; J Lähdevirta; L M Golub; T Sorsa
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis.

Authors:  A Lauhio; T Salo; Y Ding; Y T Konttinen; D Nordström; H Tschesche; J Lähdevirta; L M Golub; T Sorsa
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

9.  Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase and gelatinase.

Authors:  T Sorsa; O Lindy; Y T Konttinen; K Suomalainen; T Ingman; H Saari; S Halinen; H M Lee; L M Golub; J Hall
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Intraarticular minocycline injection in experimental synovitis.

Authors:  A Weinberger; T Ben-Gal; P Roizman; A Abramovici
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.